Ctrl

K

AbobotulinumtoxinA

Class
Biologic agents
Subclass
Neurotoxins
Substance name
AbobotulinumtoxinA
Brand names
Dysport®
Common formulations
Powder for parenteral solution
Dosage and administration
Adults patients
Cervical dystonia
250-1,000 unit(s) IM q12 weeks
Glabellar lines
50 unit(s) IM q12 weeks
Indications for use
Labeled indications
Adults
Treatment of cervical dystonia
Treatment of glabellar lines
Treatment of muscle spasticity
Children
Treatment of muscle spasticity (in patients ≥ 2 years)
Treatment of muscle spasticity (in patients ≥ 2 years) (lower limb)
Treatment of muscle spasticity (in patients ≥ 2 years) (upper limb)
Safety risks
Boxed warnings
Botulism
Use extreme caution who received the medication for a variety of conditions and a wide range of doses. Patients and caregivers should be able to identify the signs and symptoms of systemic effects after receiving an injection of a botulinum toxin, and they should seek immediate medical attention if they have worsening or unexpected difficulty swallowing or talking, trouble breathing, or muscle weakness. If systemic botulism is suspected, seek immediate medical attention. Administer antitoxin therapy, if available, and provide supportive care to manage symptoms.
Xerophthalmia, corneal diseases
Use extreme caution with a history of ocular disease. Assess the patient's ocular health before treatment and consider artificial tear supplements if needed. Advise patients to avoid rubbing their eyes excessively and follow proper eye care practices. Monitor the patient's ocular symptoms closely and discontinue or adjust the treatment as necessary. Prompt referral to an eye specialist can help in managing and addressing any corneal disorders or other ocular complications.
Contraindications
A known hypersensitivity to any botulinum toxin product, cow's milk protein (milk protein hypersensitivity), or any other component in the formulation.
Prior to administration, obtain a detailed medical history and allergy assessment.
Pre-existing infection at the proposed injection site(s).
Ensure proper aseptic technique during injection, clean the injection site with alcohol before administration, and avoid injection into areas with active infections.
Warnings and precautions
Bradycardia
Use caution with cardiac disease. Assess the patient's medical history and cardiac status, especially if they have a history of bradycardia or heart rhythm abnormalities. Closely monitor the patient's vital signs and cardiac function. If the bradycardia is severe or symptomatic, seek immediate medical attention.
Cervical dystonia, dysphagia
Use extreme caution with a history of respiratory disorders. Prior to administration, carefully assess the patient's medical history and perform a thorough physical examination, including evaluation of respiratory function and swallowing abilities. Closely monitor the patient's condition and consider immediate medical intervention. Administer supportive care, consult a specialist, and be prepared to provide respiratory support if necessary.
Dysphagia, respiratory failure
Use extreme caution with myopathy associated with neuromuscular disease. Prior to treatment, conduct a thorough assessment of the patient's medical history, particularly focusing on neuromuscular conditions and myopathy. Provide appropriate supportive care, involve a multidisciplinary team, and consider discontinuing the use of AbobotulinumtoxinA. Monitor the patient closely and be prepared to administer respiratory support if needed.
Hyperglycemia
Use caution with poorly controlled diabetes mellitus. Prior to administering AbobotulinumtoxinA, assess the patient's glucose levels, especially in those with a history of diabetes or hyperglycemia. Adjust insulin or antidiabetic medications as necessary. Encourage lifestyle modifications, such as diet and exercise, to help control blood sugar levels.
Viral infections, Creutzfeldt-Jakob disease
Use caution with a prior exposure to certain viruses. Ensure proper hygiene and aseptic techniques during the injection procedure to minimize the risk of infection. Immediately discontinue AbobotulinumtoxinA treatment. Implement appropriate infection control measures and consult with infectious disease specialists for further evaluation and management of the viral infection.
Pregnancy and breastfeeding
Pregnancy
All trimesters
Use only if benefits outweigh potential risks. Evidence of fetal harm in animals.
Breastfeeding
Little information available on breastfeeding safety.
Acceptable for use during breastfeeding.
Undetectable levels in breastfed infants.
No overt adverse effects reported in breastfed infants.
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Sign up for free to access the full drug resource